Stoke Therapeutics, Inc.
General ticker "STOK" information:
- Sector: Health Care
- Industry: Biotechnology
- Capitalization: $807.6M (TTM average)
Stoke Therapeutics, Inc. follows the US Stock Market performance with the rate: 51.4%.
Estimated limits based on current volatility of 3.0%: low 29.23$, high 31.03$
Factors to consider:
- Total employees count: 128 (+16.4%) as of 2024
- Company does not operate outside US (retrieved using AI)
- Top business risk factors: Early stage company with limited history, Regulatory and compliance, Strategic risks and growth management, Acquisition/divestiture risks, Economic downturns and volatility
- Current price 72.1% above estimated high
- Earnings for 9 months up through Q3 exceed our estimates
Stock Forecast*
* forecast is subjective and experimental, should not be used for any investment decisions
Long term estimates were made for the period from 2024-12-31 to 2026-12-31
- 2024-12-31 to 2025-12-31 estimated range: [6.89$, 18.05$]
- 2025-12-31 to 2026-12-31 estimated range: [5.26$, 14.39$]
Financial Metrics affecting the STOK estimates:
- Negative: with PPE of -6.7 at the end of fiscal year the price was high
- Negative: negative Operating income
- Negative: Operating cash flow per share per price, % of -14.31 <= 0.33
- Negative: negative Net income
- Positive: Shareholder equity ratio, % of 84.34 > 63.39
- Negative: negative Industry operating cash flow (median)
- Positive: Industry inventory ratio change (median), % of 0 <= 0
Short-term STOK quotes
Long-term STOK plot with estimates
Financial data
| YTD | 2022-12-31 | 2023-12-31 | 2024-12-31 |
|---|---|---|---|
| Operating Revenue | $12.40MM | $8.78MM | $36.55MM |
| Operating Expenses | $116.76MM | $123.55MM | $137.93MM |
| Operating Income | $-104.36MM | $-114.77MM | $-101.37MM |
| Non-Operating Income | $3.29MM | $10.07MM | $12.39MM |
| R&D Expense | $77.84MM | $82.23MM | $89.13MM |
| Income(Loss) | $-101.07MM | $-104.70MM | $-88.98MM |
| Profit(Loss)* | $-101.07MM | $-104.70MM | $-88.98MM |
| Stockholders Equity | $184.85MM | $159.56MM | $229.02MM |
| Assets | $256.07MM | $228.34MM | $271.56MM |
| Operating Cash Flow | $-31.87MM | $-81.07MM | $-86.85MM |
| Capital expenditure | $3.96MM | $1.62MM | $0.20MM |
| Investing Cash Flow | $-45.88MM | $105.95MM | $-107.47MM |
| Financing Cash Flow | $46.41MM | $53.01MM | $131.09MM |
| Earnings Per Share** | $-2.60 | $-2.38 | $-1.65 |
* Profit(Loss) attributable to entity.
** EPS are Split Adjusted, recent splits may be reflected with a delay.